CRISPR Therapeutics reports FY2022 net loss of $650.2M; exa-cel regulatory submissions complete in Europe

CRISPR Therapeutics AG

2022-FY EPS reported -$8.36 revenue$1,198,000

Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.
R&D expenses for FY2022 were $461.6M, up from $340.6M in FY2021, driven by pipeline advancement.
Net loss for FY2022 was $650.2M, compared to net income of $377.7M in FY2021, due to lower collaboration revenue.
Regulatory submissions for exa-cel (CTX001) completed in Europe; U.S. BLA rolling submission on track for Q1 2023.
Enrolling and dosing ongoing for CTX110 (CD19+ B-cell malignancies) and CTX130 (CD70+ T cell lymphomas); next-gen CAR T trials initiating.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On February 21, 2023, CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-003436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.